EGFR and cancer: Although most of the activating EGFR-mutations occurring in NSCLC before treatment have for a long time been considered mutually exclusive with other recurrent cancer-driver alterations, more recent sensitive molecular analyses have shown the concomitant occurrence of other driver-mutations in a significant percentage of untreated EGFRM+ LACs [3,10,12,42,43,44,45,46,47].